{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:46:52Z","timestamp":1779151612942,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T00:00:00Z","timestamp":1517788800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s11239-018-1622-5","type":"journal-article","created":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T07:04:30Z","timestamp":1517814270000},"page":"550-556","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibrillation: an updated meta-analysis"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9610-7408","authenticated-orcid":false,"given":"Natale Daniele","family":"Brunetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Tarantino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"De Gennaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Correale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Di Biase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,5]]},"reference":[{"key":"1622_CR1","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.cjca.2016.11.013","volume":"33","author":"RK Sandhu","year":"2017","unstructured":"Sandhu RK, Smigorowsky M, Lockwood E, Savu A, Kaul P, McAlister FA (2017) Impact of electrical cardioversion on quality of life for the treatment of atrial fibrillation. Can J Cardiol 33:450\u2013455","journal-title":"Can J Cardiol"},{"key":"1622_CR2","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/oxfordjournals.eurheartj.a060665","volume":"15","author":"L Missault","year":"1994","unstructured":"Missault L, Jordaens L, Gheeraert P, Adang L, Clement D (1994) Embolic stroke after unanticoagulated cardioversion despite prior exclusion of atrial thrombi by transoesophageal echocardiography. Eur Heart J 15:1279\u20131280","journal-title":"Eur Heart J"},{"key":"1622_CR3","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K (2016) 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893\u20132962","journal-title":"Eur Heart J"},{"issue":"21","key":"1622_CR4","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","volume":"64","author":"CT January","year":"2014","unstructured":"January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Jr., Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW (2014) 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64(21):e1\u2013e76","journal-title":"J Am Coll Cardiol"},{"key":"1622_CR5","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators (2009) Dabigatran versus Warfarin in patients with atrial fibrillation. N Engl J Med 361:1139\u20131151","journal-title":"N Engl J Med"},{"key":"1622_CR6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKET AF Investigators (2011) Rivaroxaban versus Warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883\u2013891","journal-title":"N Engl J Med"},{"key":"1622_CR7","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators (2011) Apixaban versus Warfarin in patients with atrial fibrillation. N Engl J Med 365:981\u2013992","journal-title":"N Engl J Med"},{"key":"1622_CR8","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, \u0160pinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM, ENGAGE AF-TIMI 48 Investigators (2013) Edoxaban versus Warfarin in patients with atrial fibrillation. N Engl J Med 369:2093\u20132104","journal-title":"N Engl J Med"},{"key":"1622_CR9","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.amjmed.2016.05.007","volume":"129","author":"G Renda","year":"2016","unstructured":"Renda G, Zimarino M, Ricci F, Piccini JP, Ezekowitz MD, Patel MR, Cappato R, Giugliano RP, De Caterina R (2016) Efficacy and safety of non-vitamin K antagonist oral anticoagulants after cardioversion for nonvalvular atrial fibrillation. Am J Med 129:1117\u20131123.e2","journal-title":"Am J Med"},{"key":"1622_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.amjmed.2016.09.023","volume":"130","author":"G Renda","year":"2017","unstructured":"Renda G, Ricci F, De Caterina R, Non-Vitamin K (2017) Antagonist oral anticoagulants for cardioversion in atrial fibrillation: an updated meta-analysis. Am J Med 130:457\u2013461","journal-title":"Am J Med"},{"key":"1622_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.110.977546","volume":"123","author":"R Nagarakanti","year":"2011","unstructured":"Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, Flaker G, Brugada J, Kamensky G, Parekh A, Reilly PA, Yusuf S, Connolly SJ (2011) Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 123:131\u2013136","journal-title":"Circulation"},{"key":"1622_CR12","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1016\/j.jacc.2013.02.025","volume":"61","author":"JP Piccini","year":"2013","unstructured":"Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, Hankey GJ, Hacke W, Becker RC, Nessel CC, Mahaffey KW, Fox KA, Califf RM, Breithardt G; ROCKET AF Steering Committee & Investigators (2013) Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol 61:1998\u20132006","journal-title":"J Am Coll Cardiol"},{"key":"1622_CR13","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/clc.22537","volume":"39","author":"A Plitt","year":"2016","unstructured":"Plitt A, Ezekowitz MD2, De Caterina R (2016) Nordio F4, Peterson N5, Giugliano RP4; ENGAGE AF-TIMI 48 Investigators. Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48. Clin Cardiol 39:345\u2013346","journal-title":"Clin Cardiol"},{"key":"1622_CR14","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jacc.2013.09.062","volume":"63","author":"G Flaker","year":"2014","unstructured":"Flaker G, Lopes RD, Al-Khatib SM, Hermosillo AG, Hohnloser SH, Tinga B, Zhu J, Mohan P, Garcia D, Bartunek J, Vinereanu D, Husted S, Harjola VP, Rosenqvist M, Alexander JH2, Granger CB, ARISTOTLE Committees and Investigators (2014) Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE trial (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation). J Am Coll Cardiol 63:1082\u20131087","journal-title":"J Am Coll Cardiol"},{"key":"1622_CR15","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1093\/eurheartj\/ehu367","volume":"35","author":"R Cappato","year":"2014","unstructured":"Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, Talajic M, Scanavacca M, Vardas PE, Kirchhof P, Hemmrich M, Lanius V, Meng IL, Wildgoose P, van Eickels M, Hohnloser SH, X-VeRT Investigators (2014) Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 35:3346\u20133355","journal-title":"Eur Heart J"},{"issue":"10055","key":"1622_CR16","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1016\/S0140-6736(16)31474-X","volume":"388","author":"A Goette","year":"2016","unstructured":"Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, Mercuri MF, Grosso MA, Fernandez V, Al-Saady N, Pelekh N, Merkely B, Zenin S, Kushnir M, Spinar J, Batushkin V, de Groot JR, Lip GY, ENSURE-AF Investigators (2016) Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet 388(10055):1995\u20132003","journal-title":"Lancet"},{"key":"1622_CR17","unstructured":"http:\/\/congress365.escardio.org\/Search-Results?vgnextkeyword=EMANATE\n                    \n                  . Accessed 12 Sept 2017"},{"key":"1622_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0167-5273(03)00107-4","volume":"92","author":"IA Khan","year":"2003","unstructured":"Khan IA (2003) Atrial stunning: basics and clinical considerations. Int J Cardiol 92:113\u2013128","journal-title":"Int J Cardiol"},{"key":"1622_CR19","doi-asserted-by":"publisher","first-page":"e0142397","DOI":"10.1371\/journal.pone.0142397","volume":"10","author":"I Adeniran","year":"2015","unstructured":"Adeniran I, MacIver DH, Garratt CJ, Ye J, Hancox JC, Zhang H (2015) Effects of persistent atrial fibrillation-induced electrical remodeling on atrial electro-mechanics\u2014insights from a 3D model of the human atria. PLoS ONE 10:e0142397","journal-title":"PLoS ONE"},{"key":"1622_CR20","doi-asserted-by":"publisher","first-page":"699","DOI":"10.5603\/CJ.a2015.0052","volume":"22","author":"AS Ammar","year":"2015","unstructured":"Ammar AS, Elsherbiny I, El-Dosouky II, Abd El Salam K, Abd El Hamid M, Khalil W, Ammar M (2015) Left atrial and left atrial appendage functional recovery after cardioversion in patients with recent atrial fibrillation: Serial echocardiographic study. Cardiol J 22:699\u2013707","journal-title":"Cardiol J"},{"key":"1622_CR21","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S0735-1097(98)00585-3","volume":"33","author":"PB Sparks","year":"1999","unstructured":"Sparks PB, Jayaprakash S, Mond HG, Vohra JK, Grigg LE, Kalman JM (1999) Left atrial mechanical function after brief duration atrial fibrillation. J Am Coll Cardiol 33:342\u2013349","journal-title":"J Am Coll Cardiol"},{"key":"1622_CR22","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.resuscitation.2005.07.021","volume":"68","author":"CD Deakin","year":"2006","unstructured":"Deakin CD, Ambler JJ (2006) Post-shock myocardial stunning: a prospective randomised double-blind comparison of monophasic and biphasic waveforms. Resuscitation 68:329\u2013333","journal-title":"Resuscitation"},{"key":"1622_CR23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40256-013-0061-0","volume":"14","author":"Y Wang","year":"2014","unstructured":"Wang Y, Bajorek B (2014) New oral anticoagulants in practice: pharmacological and practical considerations. Am J Cardiovasc Drugs 14:175\u2013189","journal-title":"Am J Cardiovasc Drugs"},{"key":"1622_CR24","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0140-6736(16)31277-6","volume":"388","author":"JP Piccini","year":"2016","unstructured":"Piccini JP, Fauchier L (2016) Rhythm control in atrial fibrillation. Lancet 388:829\u2013840","journal-title":"Lancet"},{"key":"1622_CR25","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1093\/eurheartj\/ehu046","volume":"35","author":"S Halvorsen","year":"2014","unstructured":"Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, Granger CB, Hanna M, Held C, Husted S, Hylek EM, Jansky P, Lopes RD, Ruzyllo W, Thomas L, Wallentin L (2014) Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 35:1864\u20131872","journal-title":"Eur Heart J"},{"issue":"5","key":"1622_CR26","doi-asserted-by":"publisher","first-page":"e003432","DOI":"10.1161\/JAHA.116.003432","volume":"5","author":"ET Kato","year":"2016","unstructured":"Kato ET, Giugliano RP, Ruff CT, Koretsune Y, Yamashita T, Kiss RG, Nordio F, Murphy SA, Kimura T, Jin J, Lanz H, Mercuri M, Braunwald E, Antman EM (2016) Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc 5(5):e003432","journal-title":"J Am Heart Assoc"},{"key":"1622_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ahj.2016.06.008","volume":"179","author":"MD Ezekowitz","year":"2016","unstructured":"Ezekowitz MD, Pollack CV, Sanders P, Halperin JL, Spahr J, Cater N, Petkun W, Breazna A, Kirchhof P, Oldgren J (2016) Apixaban compared with parenteral heparin and\/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial. Am Heart J 179:59\u201368","journal-title":"Am Heart J"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-018-1622-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-018-1622-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-018-1622-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T19:20:38Z","timestamp":1549308038000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-018-1622-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,5]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["1622"],"URL":"https:\/\/doi.org\/10.1007\/s11239-018-1622-5","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,5]]},"assertion":[{"value":"5 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no potential conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}